Health

    Botanix Pharmaceuticals issues first Sofdra prescriptions

    Article Image

    Botanix Pharmaceuticals (ASX: BOT), a clinical dermatology company, has issued its first prescriptions for Sofdra (sofpironium) topical gel, 12.45% to patients.

    This follows the Food and Drug Administration approval for Sofdra and marks Botanix's transition to a revenue-generating commercial enterprise with a full launch anticipated in the first quarter of 2025.

    The Sofdra Patient Experience Program was launched in collaboration with the International Hyperhidrosis Society.

    The initiative allowed patients to attend webinars, complete health questionnaires, and proceed through telehealth to receive prescriptions.

    Sofdra's first prescriptions have been delivered to patients within 48 hours of diagnosis. "We are pleased to note that insurance coverage has unfolded as anticipated and is in line with the expectations we have outlined previously," said Vince Ippolito, Executive Chairman of Botanix Pharmaceuticals.

    Botanix has built an inventory and tested logistics to support the product's demand.

    The company is prepared for variations in sales forecasts, which will commence with a full commercial rollout in early 2025.

    The Company has grown its team to prepare for launch, integrating data, pharmacy, and telemedicine systems for a smoother patient experience.

    A wider digital program is scheduled for the second quarter of 2025, following the sales force deployment.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa